Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Stocks That Could Help You Send Your Kids to College

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A college education isn't getting any cheaper. Pfizer, A.O. Smith, and Ceridian HCM could help put a diploma within reach.

You don't need to be told that the cost of a college education is rising faster than the rate of inflation or that you'll need a king's ransom to pay for four years of Junior's schooling. But you could use some help finding a stock today that might be worth a royal sum some 18 years down the road.

Three Motley Fool contributors take a look at why Pfizer ( PFE -0.62% ), A.O. Smith ( AOS 0.11% ), and Ceridian HCM ( CDAY 1.60% ) could be the stocks that help pay for Junior's sheepskin.

Smiling group of young people in graduating caps and gowns.

Image source: Getty Images.

A low-risk value stock

George Budwell (Pfizer): Buying stocks and holding them for long periods of time can be a great way to help cover the enormous costs of sending a child to college. This strategy, though, only works if you buy the right types of stocks that can power higher regardless of market conditions. Pharma behemoth Pfizer fits this profile nicely. 

Why is Pfizer a great stock to own for long periods of time? For one, this blue-chip drugmaker has proven its ability to create value for shareholders, even under less-than-ideal conditions.

Over the past few years, for instance, Pfizer has been stung by a host of patent expires for top-selling drugs such as Lipitor, Celebrex, and Viagra -- costing it billions in annual revenue in the process. Nevertheless, the company's shares have still managed to produce a total return on capital of 72% over the last five years (including dividends). That's some of the best returns on capital among large-cap healthcare stocks in general or big pharma stocks in particular in the past five years. 

Next up, Pfizer is close to finally pushing beyond the last of its major patent issues. Once the nerve pain medication Lyrica goes off patent in the U.S. at the end of this year, the company will then be free to focus squarely on its high-powered lineup of newer drugs that include the breast cancer medicine Ibrance and the breakout blood thinner Eliquis, among several others. As a result, this titan of the pharma industry should be able to continue delivering top-notch returns on capital for a long time to come.  

A high-growth play from a boring industry

Neha Chamaria (A.O. Smith): When you're talking about a stock that could help you fund your child's higher education, you want to find a potential multibagger in the making. Companies with a solid foothold in a promising industry stand a fair chance to be one, which is why I'd recommend you consider A.O. Smith.

Now, A.O. Smith doesn't belong to high-flying sectors like technology, but it's also a fine example of how beautiful boring can sometimes be. As a manufacturer of water heaters and boilers with presence in more than 60 countries, the company is catering to a market that'll likely remain big unless someone invents better ways to heat water or winters become a thing of history. A.O. Smith also recently forayed into the water treatment industry in China.

A.O. Smith's sales and adjusted earnings per share (that is, excluding the impact of nonoperational items such as pension, tax reforms, and restructuring) have growth at compound annual rates of 10% and 25%, respectively, since 2010. Credit largely goes to a judicious mix of acquisitions and growth initiatives in high-potential markets like China and India. These two, in fact, could be the biggest growth markets for A.O. Smith in coming years: Its sales from China alone crossed $1 billion last year, growing at a compound annual rate of 21% in the past decade.

I expect A.O. Smith stock to generate rich returns in the long term for two reasons. First, the company's growth moves to tap global opportunities should consistently add value to its top and bottom lines, which should reflect in its share price. Second, as a Dividend Aristocrat, A.O. Smith has a great dividend history: In October, management raised dividends for the second time this year and now boasts a solid five-year dividend compound annual growth rate of 30%. This combination of potential EPS accretion and dividend growth should work well in favor of A.O. Smith shares in the coming years.

Not your typical day laborer

Rich Duprey (Ceridian HCM): Payroll processing is a necessary function of any business, but its complexities usually result in businesses outsourcing the operation to a third party. It's a burgeoning industry with a diverse array of competitors, from smaller shops like Paycom and Workday to large outfits such as ADP.

Ceridian HCM is new to the public markets, having just IPO'd in April, but its lineage stretches back to the 1950s and Control Data Corp., and more recently (1990s) to information services firm Ceridian. It was the acquisition of Dayforce, a software-as-a-service provider for HR and related activities that ultimately led to the creation of Ceridian HCM.

What separates this HCM business -- HCM stands for human capital management -- from everyone else is its ability to process same-day transactions, a necessary requirement of the on-demand and gig economy. According to some estimates, 40% of the U.S. workforce will work for themselves by 2020. Ceridian's flagship Dayforce cloud platform is adding on-demand pay functionality that will enable employees to request a payout based on their earnings at any time. It's the first of its kind in the industry.

Ceridian has gained more than 70% since its IPO, but there's good reason to think it can go much higher still, as it establishes itself in the forefront of the contingent employee workforce that could reshape the job market as we know it.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$51.40 (-0.62%) $0.32
A. O. Smith Corporation Stock Quote
A. O. Smith Corporation
$82.98 (0.11%) $0.09
Ceridian HCM Holding Inc. Stock Quote
Ceridian HCM Holding Inc.
$108.57 (1.60%) $1.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.